January 30, 2026 11:01 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Big setback for Modi govt: Supreme Court stays controversial UGC Equity Regulations 2026 amid student protests | ‘Mother of all deals’: PM Modi says India–EU FTA is for 'ambitious India' | Delhi HC snubs Sameer Wankhede’s defamation plea over Aryan Khan's Netflix series | Maharashtra in shock: Ajit Pawar dies in plane crash — funeral sees emotional gathering of political heavyweights | India, Canada eye 10-year uranium pact during PM Carney’s March visit | 'None will be harassed': Dharmendra Pradhan breaks silence as UGC rules trigger student protests | Massive student uprising rocks Modi govt over new UGC rules on caste discrimination | Ajit Pawar no more: Maharashtra Deputy CM dies in Baramati plane crash | India, EU sign historic trade deal | ‘Dear Indian Friends’: Macron’s Republic Day message to India melts hearts
Corona Remedies
Corona Remedies listed at 38% premium. Photo: ChatGPT

Corona Remedies storms Dalal Street! Shares list at 38% premium on debut

| @indiablooms | Dec 15, 2025, at 11:19 am

Mumbai/IBNS: Pharmaceutical firm Corona Remedies made a strong debut on the stock market on Monday, listing at a 38% premium over its IPO price on the National Stock Exchange (NSE), media reports said.

The company’s shares were listed at ₹1,470 apiece on the NSE, marking a 38.42% premium over the issue price.

On the BSE, the stock debuted at ₹1,452 per share, a 36.72% premium.

The ₹655.37-crore IPO, which was entirely an offer for sale, had a price band of ₹1,008–1,062 per share and was open for subscription from December 8 to 10.

Headquartered in Ahmedabad, Gujarat, Corona Remedies is an Indian pharmaceutical company with a strong presence in branded generics, catering to both chronic and acute therapy segments.

The robust listing underscored strong investor confidence in the company’s growth outlook and financial performance, reflecting sustained demand for quality pharma IPOs in the Indian market.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm